866-997-4948 (US-Canada Toll Free)

Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns

Published By :

GBI Research

Published Date : 2014-03-13

Category :

Therapeutic Area

No. of Pages : 74

Product Synopsis

GBI Research has released its pharma research: ‘Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns ’, which provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the epilepsy market in the major developed markets amounted to an estimated $3.4 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.9% to reach $4.5... Read More

Table Of Content

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Pathophysiology
2.6 Co-morbidities/Complications
2.7 Diagnosis
2.8 Prognosis
2.9 Treatment Efficacy
2.10 Treatment Options
2.10.1 Ion Channel Modulators
2.10.2 GABA-ergic Facilitation
2.10.3 Excitatory Amino Acid Inhibitors
2.10.4 Synaptic Modulators
2.11 Non-pharmacological Management
2.11.1 Lobectomy and Lesionectomy
2.11.2 Ketogenic Diet and Modified Atkins Diet
2.11.3 Vagus Nerve Stimulation

3 Epilepsy Therapeutic Landscape
3.1 Overview
3.2 Lyrica (pregabalin)
3.3 Lamictal (lamotrigine)
3.4 Keppra (levetiracetam)
3.5 Zonegran (zonisamide)
3.6 Vimpat (lacosamide)
3.7 Aptiom/Zebinix (eslicarbazepine acetate)
3.8 Fycompa (perampanel)
3.9 Trobalt/Potiga (ezogabine/retigabine)
3.10 Banzel/Inovelon (rufinamide)
3.11 Comparative Efficacy and Safety of Marketed Products

4 Pipeline for Epilepsy Therapeutics
4.1 Overall Pipeline
4.2 Pipeline by Mechanism of Action
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Patient Enrolment and Clinical Trial Size
4.3.3 Clinical Trial Duration
4.4 Promising Pipeline Candidates
4.4.1 Brivaracetam – UCB
4.4.2 Ganaxolone – Marinus Pharmaceuticals

5 Epilepsy Therapeutics Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Major Developed Markets
5.1.2 The US
5.1.3 Top Five EU Countries
5.1.4 Japan
5.1.5 Canada
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers

6 Deals and Strategic Consolidations
6.1 Deals Analysis
6.2 Research and Development Co-development Agreements
6.3 Research and Development Licensing Agreements

7 Appendix
7.1 Abbreviations
7.2 References
7.3 References for Heat Maps
7.4 Pipeline Products by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 IND-filed and Phase 0
7.4.4 Phase I
7.4.5 Phase II
7.4.6 Phase III
7.4.7 Pre-registration
7.5 Market Forecasting Data Tables to 2019
7.5.1 Major Developed Markets
7.5.2 US
7.5.3 UK
7.5.4 France
7.5.5 Germany
7.5.6 Italy
7.5.7 Spain
7.5.8 Japan
7.5.9 Canada
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

List of Tables

Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013
Table 10: Epilepsy Therapeutics, Major Developed Markets, Market Forecast, 2012–2019
Table 11: Epilepsy Therapeutics, US, Market Forecast, 2012–2019
Table 12: Epilepsy Therapeutics, UK, Market Forecast, 2012–2019
Table 13: Epilepsy Therapeutics, France, Market Forecast, 2012–2019
Table 14: Epilepsy Therapeutics, Germany, Market Forecast, 2012–2019
Table 15: Epilepsy Therapeutics, Italy, Market Forecast, 2012–2019
Table 16: Epilepsy Therapeutics, Spain, Market Forecast, 2012–2019
Table 17: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019
Table 18: Epilepsy Therapeutics, Canada, Market Forecast, 2012–2019

List of Figures

Figure 1: Epilepsy Therapeutics, Epidemiology, Major Developed Markets, 2012
Figure 2: Epilepsy Therapeutics, Major Developed Markets, Approved Anti-epileptic Drugs, 2013
Figure 3: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013
Figure 4: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013
Figure 5: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013
Figure 6: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013
Figure 7: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013
Figure 8: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013
Figure 9: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013
Figure 10: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Failure Rate, 2013
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013
Figure 13: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013
Figure 14: Epilepsy Therapeutics, Major Developed Markets, Treatment Usage Pattern and Market Size, 2012–2019
Figure 15: Epilepsy Therapeutics, US, Treatment Usage Pattern, ACoT and Market Size, 2012–2019
Figure 16: Epilepsy Therapeutics, Top Five EU Countries, Treatment Patterns (‘000), 2012–2019
Figure 17: Epilepsy Therapeutics, Top Five EU Countries, Annual Cost of Treatment ($), 2012–2019
Figure 18: Epilepsy Therapeutics, Top Five EU Countries, Market Size ($m), 2012–2019
Figure 19: Epilepsy Therapeutics, Japan, Treatment Usage Pattern, ACoT and Market Size, 2012–2019
Figure 20: Epilepsy Therapeutics, Canada, Market Size, 2012–2019
Figure 21: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013
Figure 22: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013
Figure 23: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013
Figure 24: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013
Figure 25: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

Full Name * Message
Your Email *
Job Title
Phone No. * (Pls. Affix Country Code) Security Code *

Upcoming Reports

  • Portable Medical Electronic Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    By - Transparency

    The portable medical electronic industry is witnessing significant growth and adoption in recent years. Mobilization of medical devices has driven the healthcare industry as the use of medical equipments has expanded beyond hospitals to homecare environments. Due to the presence of microprocessors the devices manufactured are more portable, compact and are light in weight. Rapid technological advancements in semiconductors provide large scale integration and reduced power consumption. Portable medical equipments comprises of various features such as analog front-ends for data...

  • Poland: iron and steel windows market

    By - Williams and Marshal Strategy

    This report presents a comprehensive overview of the iron and steel windows market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the iron and steel windows market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...

  • Flame Retardant Chemicals Market - Global Industry Analysis, Size, Market Share, Growth, Trends and Forecast, 2012 - 2018

    By - Transparency

    Flame retardant chemicals are halogen, nitrogen and phosphorous containing compounds which are added to plastics and rubber in order to reduce the magnitude of burning and inhibit flames. They are increasingly being used in construction of buildings, textiles, and automobile and electronic parts manufacturing.  These additives do not alter the property of the parent material but delays if not completely stop the burning of the material.  With the growing safety regulations with regards to fire and the extensive use of flammable materials, these chemicals have...